Recombinant human activated protein C, package labeling, and hemorrhage risks

Critical Care Medicine

Volumn 37, Issue 1, 2009, Pages 327-329

  Sweeney, Daniel A ^a   Natanson, Charles ^a   Eichacker, Peter Q ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

bleeding; Prescription drug labeling; Recombinant human activated protein C

Indexed keywords

DROTRECOGIN; HEPARIN; ROSUVASTATIN; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

BLEEDING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG LABELING; DRUG PACKAGING; EDITORIAL; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; SAMPLE SIZE; SAMPLING ERROR; SEPSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; CHEMICALLY INDUCED DISORDER; NOTE; RISK FACTOR;

ANTI-INFECTIVE AGENTS; DRUG LABELING; HEMORRHAGE; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 59649090795     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181935102     Document Type: Editorial

References (15)

1. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
2. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030
3. Product Information - Xigris. Eli Lilly and Co., Indianapolis, Indiana. 2007. Available at: http://www.xigris.com/330-safety.jsp. Accessed November 20, 2008
4. Gentry CA, Gross KB, Sud B, et al: Adverse outcomes associated with the use of dro-trecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009; 37:19-25
5. Bertolini G, Rossi C, Anghileri A, et al: Use of Drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey. Intensive Care Med 2007; 33: 426-434
6. Kanji S, Perreault MM, Chant C, et al: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study. Intensive Care Med 2007; 33:517-523
7. Levi M, Levy M, Williams MD, et al: Prophylactic heparin in patients with severe sepsis treated with Drotrecogin alfa (activated). Am J Respir Crit Care Med 2007; 176: 483-490
8. Steingrub J, Sanchez P, Zeckel M, et al: Safety of Drotrecogin alfa (activated): Results of MERCURY, a retrospective multicenter observation study. Crit Care Med 2003; 31: A117
9. Tanzi M: Use of Drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis: Medical use evaluation by Novation, the supply company of VHA and UHC. Novation 2004
10. Wheeler A, Steingrub J, Schmidt GA, et al: A retrospective observational study of Drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. Crit Care Med 2008; 36:14-23
11. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
12. Vincent JL, Bernard GR, Beale R, et al: Dro-trecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266-2277
13. Guidance for Industry: Warnings and Pre- cautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products - Content and Format. Available at: http:// www.fda.gov/cber/gdlns/ boxwarlb.htm. Accessed November 20, 2008
14. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843
15. Friedrich JO, LaRosa SP, Baillie JK, et al: Drotrecogin alfa (activated) in severe sepsis. N Engl J Med 2006; 354:94-96 16. National Library of Medicine: Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock. In: ClinicalTrials. gov [Internet]. Bethesda (MD), National Library of Medicine (US), 2000-2008. Available at: http:// clinicaltrials.gov/ct2/show/ NCT00604214?term=sepsis+xigris&rank=7 NLM. Identifier: NCT00604214. Accessed November 20, 2008